Literature DB >> 15128615

Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis.

K T M Fernando1, M A McLean, D T Chard, D G MacManus, C M Dalton, K A Miszkiel, R M Gordon, G T Plant, A J Thompson, D H Miller.   

Abstract

Normal-appearing white matter (NAWM) in established multiple sclerosis has been shown to be abnormal using a variety of magnetic resonance (MR) techniques, including proton MR spectroscopy ((1)H-MRS), although the stage at which these changes first appear is less clear. Using a 1.5 T scanner and single-voxel (1)H-MRS [TR 3000 ms, TE 30 ms, point-resolved spectroscopy (PRESS) localization], we determined NAWM metabolite concentrations in 96 patients a mean of 19 weeks (range 12-28 weeks) after onset of a clinically isolated syndrome (CIS) suggestive of multiple sclerosis and in 44 healthy control subjects. Absolute concentrations of N-acetyl-aspartate, total creatine and phosphocreatine (Cr), choline-containing compounds, glutamate plus glutamine, and myo-inositol (Ins) were estimated automatically using the LCModel. Compared with control subjects, the concentration of Ins was elevated in CIS NAWM (mean 3.31 mM, SD 0.86 versus mean 3.82 mM, SD 1.06; P = 0.001). The increase in Ins was also seen in the patient subgroup with abnormal T2-weighted MRI (mean 3.88 mM, SD 1.10; P = 0.001) and in those who satisfied the McDonald criteria for multiple sclerosis (mean 4.04 mM, SD 1.31; P = 0.001). An increase in Cr was also observed in CIS NAWM (P = 0.023), but other metabolites did not significantly differ between the whole CIS group and control subjects. There was no significant correlation between NAWM Ins and T2 lesion load. The early increase in Ins may reflect a process of pathogenic importance in multiple sclerosis NAWM. Follow-up studies will investigate whether the increase in NAWM Ins is of prognostic importance for future relapses and disability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15128615     DOI: 10.1093/brain/awh153

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  52 in total

1.  Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM.

Authors:  Radhika Srinivasan; Joanna J Phillips; Scott R Vandenberg; Mei-Yin C Polley; Gabriela Bourne; Alvin Au; Andrea Pirzkall; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2010-07-20       Impact factor: 12.300

Review 2.  Magnetic resonance spectroscopy in the monitoring of multiple sclerosis.

Authors:  Ponnada A Narayana
Journal:  J Neuroimaging       Date:  2005       Impact factor: 2.486

Review 3.  Pharmacological treatment of early multiple sclerosis.

Authors:  Olaf Stüve; Jeffrey L Bennett; Bernhard Hemmer; Heinz Wiendl; Michael K Racke; Amit Bar-Or; Wei Hu; Robert Zivadinov; Martin S Weber; Scott S Zamvil; Maria F Pacheco; Til Menge; Hans-Peter Hartung; Bernd C Kieseier; Elliot M Frohman
Journal:  Drugs       Date:  2008       Impact factor: 9.546

4.  A brain magnetization transfer MRI study with a clinical follow up of about four years in patients with clinically isolated syndromes suggestive of multiple sclerosis.

Authors:  Antonio Gallo; Marco Rovaris; Beatrice Benedetti; Maria Pia Sormani; Roberto Riva; Angelo Ghezzi; Vittorio Martinelli; Andrea Falini; Giancarlo Comi; Massimo Filippi
Journal:  J Neurol       Date:  2007-02-14       Impact factor: 4.849

5.  A 3-year diffusion tensor MRI study of grey matter damage progression during the earliest clinical stage of MS.

Authors:  Marco Rovaris; Elda Judica; Antonia Ceccarelli; Angelo Ghezzi; Vittorio Martinelli; Giancarlo Comi; Massimo Filippi
Journal:  J Neurol       Date:  2008-06-13       Impact factor: 4.849

Review 6.  MRI in multiple sclerosis: what's inside the toolbox?

Authors:  Mohit Neema; James Stankiewicz; Ashish Arora; Zachary D Guss; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

Review 7.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.

Authors:  Àlex Rovira; Mike P Wattjes; Mar Tintoré; Carmen Tur; Tarek A Yousry; Maria P Sormani; Nicola De Stefano; Massimo Filippi; Cristina Auger; Maria A Rocca; Frederik Barkhof; Franz Fazekas; Ludwig Kappos; Chris Polman; David Miller; Xavier Montalban
Journal:  Nat Rev Neurol       Date:  2015-07-07       Impact factor: 42.937

8.  Prognostic value of high-field proton magnetic resonance spectroscopy in patients presenting with clinically isolated syndromes suggestive of multiple sclerosis.

Authors:  Mike P Wattjes; Michael Harzheim; Götz G Lutterbey; Manuela Bogdanow; Stephan Schmidt; Hans H Schild; Frank Träber
Journal:  Neuroradiology       Date:  2007-11-03       Impact factor: 2.804

9.  White matter hemodynamic abnormalities precede sub-cortical gray matter changes in multiple sclerosis.

Authors:  Andrew W Varga; Glyn Johnson; James S Babb; Joseph Herbert; Robert I Grossman; Matilde Inglese
Journal:  J Neurol Sci       Date:  2009-01-31       Impact factor: 3.181

10.  Dirty-appearing white matter in multiple sclerosis: preliminary observations of myelin phospholipid and axonal loss.

Authors:  G R W Moore; C Laule; A Mackay; E Leung; D K B Li; G Zhao; A L Traboulsee; D W Paty
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.